Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic?

References

• Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N. Engl. J. Med. 350(11), 1118–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127(5 Suppl. 1), S56–S61 (2004).
   Web of Science ®Google Scholar
• Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin. Liver Dis. 19(3), 271–285 (1999).
   PubMed Web of Science ®Google Scholar
• Harkisoen S, Arends JE, van Erpecum KJ, van den Hoek A, Hoepelman AI. Hepatitis B viral load and risk of HBV-related liver disease: from East to West? Ann. Hepatol. 11(2), 164–171 (2012).
   PubMedGoogle Scholar
• Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64(1), 51–68 (2000).
   PubMed Web of Science ®Google Scholar
• Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56, 651–693 (1987).
   PubMed Web of Science ®Google Scholar
• Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281(5733), 646–650 (1979).
   PubMed Web of Science ®Google Scholar
• Twu JS, Schloemer RH. Transcriptional trans-activating function of hepatitis B virus. J. Virol. 61(11), 3448–3453 (1987).
   PubMed Web of Science ®Google Scholar
• Wollersheim M, Debelka U, Hofschneider PH. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 3(5), 545–552 (1988).
   PubMedGoogle Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48(2), 335–352 (2008).
   PubMed Web of Science ®Google Scholar
• Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 14(19), 4747–4757 (1995).
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol. 78(23), 12725–12734 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng DL, Zhang L, Cheng N et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J. Hepatol. 50(2), 377–387 (2009).
   PubMedGoogle Scholar
• Benhenda S, Ducroux A, Riviere L et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J. Virol. 87(8), 4360–4371 (2013).
   PubMed Web of Science ®Google Scholar
• Belloni L, Pollicino T, De Nicola F et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA 106(47), 19975–19979 (2009).
   Google Scholar
• Rahmani Z, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J. Virol. 74(6), 2840–2846 (2000).
   PubMed Web of Science ®Google Scholar
• Elmore LW, Hancock AR, Chang SF et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl Acad. Sci. USA 94(26), 14707–14712 (1997).
   Google Scholar
• Avila MA, Lu KP. Hepatitis B virus x protein and pin1 in liver cancer: “les liaisons dangereuses”. Gastroenterology 132(3), 1180–1183 (2007).
   PubMedGoogle Scholar
• Xie N, Huang K, Zhang T et al. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. J. Proteomics. 75(3), 725–739 (2012).
   PubMedGoogle Scholar
• Tong A, Wu L, Lin Q et al. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 8(10), 2012–2023 (2008).
   PubMedGoogle Scholar
• Dengjel J, Kratchmarova I, Blagoev B. Mapping protein-protein interactions by quantitative proteomics. Methods Mol. Biol. 658, 267–278 (2010).
   PubMedGoogle Scholar
• Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J. Viral. Hepat. 9(5), 323–331 (2002).
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 294(5550), 2376–2378 (2001).
   PubMed Web of Science ®Google Scholar
• Keasler VV, Hodgson AJ, Madden CR, Slagle BL. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 81(6), 2656–2662 (2007).
   PubMed Web of Science ®Google Scholar
• Choi BH, Park GT, Rho HM. Interaction of hepatitis B viral X protein and CCAAT/ enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J. Biol. Chem. 274(5), 2858–2865 (1999).
   PubMedGoogle Scholar
• Cougot D, Allemand E, Riviere L et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci. Signal. 5(205), ra1 (2012).
   PubMedGoogle Scholar
• Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J. Virol. 85(2), 987–995 (2011).
   PubMedGoogle Scholar
• Shukla R, Yue J, Siouda M et al. Proinflammatory cytokine TNF-alpha increases the stability of hepatitis B virus X protein through NF-kappaB signaling. Carcinogenesis 32(7), 978–985 (2011).
   PubMedGoogle Scholar
• Sir D, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc. Natl Acad. Sci. USA 107(9), 4383–4388 (2010).
   Google Scholar
• Qadri I, Maguire HF, Siddiqui A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc. Natl Acad. Sci. USA 92(4), 1003–1007 (1995).
   Google Scholar
• Cheong JH, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 14(1), 143–150 (1995).
   PubMed Web of Science ®Google Scholar
• Lin Y, Nomura T, Cheong J, Dorjsuren D, Iida K, Murakami S. Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5. J. Biol. Chem. 272(11), 7132–7139 (1997).
   PubMed Web of Science ®Google Scholar
• Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc. Natl Acad. Sci. USA 93(20), 10578–10583 (1996).
   Google Scholar
• Jaitovich-Groisman I, Benlimame N, Slagle BL et al. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J. Biol. Chem. 276(17), 14124–14132 (2001).
   PubMed Web of Science ®Google Scholar
• Cougot D, Wu Y, Cairo S et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem. 282(7), 4277–4287 (2007).
   PubMed Web of Science ®Google Scholar
• Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13(2), 123–135 (2013).
   PubMed Web of Science ®Google Scholar
• Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem. J. 416(2), 219–230 (2008).
   PubMedGoogle Scholar
• Kong HJ, Hong SH, Lee MY, Kim HD, Lee JW, Cheong J. Direct binding of hepatitis B virus X protein and retinoid X receptor contributes to phosphoenolpyruvate carboxykinase gene transactivation. FEBS Lett. 483(2–3), 114–118 (2000).
   PubMedGoogle Scholar
• Tanaka Y, Kanai F, Ichimura T et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene 25(4), 633–642 (2006).
   PubMedGoogle Scholar
• Moon EJ, Jeong CH, Jeong JW et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J. 18(2), 382–384 (2004).
   PubMedGoogle Scholar
• Sung WK, Lu Y, Lee CW, Zhang D, Ronaghi M, Lee CG. Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. J. Biol. Chem. 284(33), 21941–21954 (2009).
   PubMedGoogle Scholar
• Russell WE, Coffey RJ Jr, Ouellette AJ, Moses HL. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc. Natl Acad. Sci. USA 85(14), 5126–5130 (1988).
   Google Scholar
• Bertran E, Crosas-Molist E, Sancho P et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology doi:10.1002/hep.26597 (2013) (Epub ahead of print).
   PubMedGoogle Scholar
• Yoo YD, Ueda H, Park K et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J. Clin. Invest. 97(2), 388–395 (1996).
   PubMed Web of Science ®Google Scholar
• Lee DK, Park SH, Yi Y et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev. 15(4), 455–466 (2001).
   PubMed Web of Science ®Google Scholar
• Lee YH, Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem. 273(39), 25510–25515 (1998).
   PubMed Web of Science ®Google Scholar
• Cong YS, Yao YL, Yang WM, Kuzhandaivelu N, Seto E. The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein. J. Biol. Chem. 272(26), 16482–16489 (1997).
   PubMedGoogle Scholar
• Kim JS, Rho B, Lee TH, Lee JM, Kim SJ, Park JH. The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6. Biochem. Biophys. Res. Commun. 351(1), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Khattar E, Mukherji A, Kumar V. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation. FEBS J. 279(7), 1220–1230 (2012).
   PubMedGoogle Scholar
• Zhang T, Xie N, He W et al. An integrated proteomics and bioinformatics analyses of hepatitis B virus X interacting proteins and identification of a novel interactor apoA-I. J. Proteomics. 84, 92–105 (2013).
   PubMed Web of Science ®Google Scholar
• Banks L, Pim D, Thomas M. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Sci. 28(8), 452–459 (2003).
   PubMed Web of Science ®Google Scholar
• Shackelford J, Pagano JS. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination. Mol. Cell Biol. 24(12), 5089–5093 (2004).
   PubMedGoogle Scholar
• Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5(9), 739–751 (2004).
   PubMed Web of Science ®Google Scholar
• Kalra N, Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett. 580(2), 431–436 (2006).
   PubMedGoogle Scholar
• Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol. 70(8), 5582–5591 (1996).
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J. Virol. 73(9), 7231–7240 (1999).
   PubMed Web of Science ®Google Scholar
• Li T, Robert EI, van Breugel PC, Strubin M, Zheng N. A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat. Struct. Mol. Biol. 17(1), 105–111 (2010).
   PubMed Web of Science ®Google Scholar
• Jung JK, Kwun HJ, Lee JO, Arora P, Jang KL. Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53. J. Gen. Virol. 88(Pt 8), 2144–2154 (2007).
   PubMedGoogle Scholar
• Cui F, Wang Y, Wang J et al. The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics 6(2), 498–504 (2006).
   PubMed Web of Science ®Google Scholar
• Hu G, Chung YL, Glover T, Valentine V, Look AT, Fearon ER. Characterization of human homologs of the Drosophila seven in absentia (sina) gene. Genomics 46(1), 103–111 (1997).
   PubMedGoogle Scholar
• Zhao J, Wang C, Wang J et al. E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein. FEBS Lett. 585(19), 2943–2950 (2011).
   PubMedGoogle Scholar
• Li Y, Lau YF. TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. Oncogene 27(47), 6141–6150 (2008).
   PubMedGoogle Scholar
• Tu Y, Wu W, Wu T et al. Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J. Biol. Chem. 282(16), 11722–11731 (2007).
   PubMedGoogle Scholar
• Kido T, Ou JH, Lau YF. The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway. PLoS ONE 6(7), e22979 (2011).
   Google Scholar
• Xian L, Zhao J, Wang J et al. p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2. Mol. Biol. Rep. 37(6), 2935–2940 (2010).
   PubMedGoogle Scholar
• Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61(1), 49–59 (1990).
   PubMed Web of Science ®Google Scholar
• Ling MT, Chiu YT, Lee TK et al. Id-1 induces proteasome-dependent degradation of the HBX protein. J. Mol. Biol. 382(1), 34–43 (2008).
   PubMedGoogle Scholar
• Kim HY, Cho HK, Yoo SK, Cheong JH. Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation. Exp. Mol. Med. 44(10), 622–632 (2012).
   PubMedGoogle Scholar
• Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69(3), 1851–1859 (1995).
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8(5), 1109–1117 (1993).
   PubMedGoogle Scholar
• Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci USA 91(6), 2230–2234 (1994).
   Google Scholar
• Marusawa H, Matsuzawa S, Welsh K et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22(11), 2729–2740 (2003).
   PubMedGoogle Scholar
• Liu H, Yuan Y, Guo H et al. Hepatitis B virus encoded X protein suppresses apoptosis by inhibition of the caspase-independent pathway. J. Proteome Res. 11(10), 4803–4813 (2012).
   PubMedGoogle Scholar
• Chirillo P, Pagano S, Natoli G et al. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc. Natl Acad. Sci. USA 94(15), 8162–8167 (1997).
   Google Scholar
• Terradillos O, Pollicino T, Lecoeur H et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 17(16), 2115–2123 (1998).
   PubMedGoogle Scholar
• Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J. Biol. Chem. 273(1), 381–385 (1998).
   PubMedGoogle Scholar
• Shintani Y, Yotsuyanagi H, Moriya K et al. Induction of apoptosis after switch-on of the hepatitis B virus X gene mediated by the Cre/loxP recombination system. J. Gen. Virol. 80(Pt 12), 3257–3265 (1999).
   PubMedGoogle Scholar
• Schuster R, Gerlich WH, Schaefer S. Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene 19(9), 1173–1180 (2000).
   PubMedGoogle Scholar
• Geng X, Harry BL, Zhou Q et al. Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 109(45), 18465–18470 (2012).
   Google Scholar
• Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 92(3), 351–366 (1998).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanai F, Kawakami T et al. Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochem. Biophys. Res. Commun. 318(2), 461–469 (2004).
   PubMedGoogle Scholar
• Rahmani Z, Maunoury C, Siddiqui A. Isolation of a novel human voltage-dependent anion channel gene. Eur. J. Hum. Genet. 6(4), 337–340 (1998).
   PubMedGoogle Scholar
• Sorgato MC, Moran O. Channels in mitochondrial membranes: knowns, unknowns, and prospects for the future. Crit. Rev. Biochem. Mol. Biol. 28(2), 127–171 (1993).
   PubMedGoogle Scholar
• Colombini M. A candidate for the permeability pathway of the outer mitochondrial membrane. Nature 279(5714), 643–645 (1979).
   PubMedGoogle Scholar
• Liu MY, Colombini M. Regulation of mitochondrial respiration by controlling the permeability of the outer membrane through the mitochondrial channel, VDAC. Biochim. Biophys. Acta 1098(2), 255–260 (1992).
   PubMedGoogle Scholar
• Rostovtseva T, Colombini M. ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane. J. Biol. Chem. 271(45), 28006–28008 (1996).
   PubMedGoogle Scholar
• Green DR, Reed JC. Mitochondria and apoptosis. Science 281(5381), 1309–1312 (1998).
   PubMed Web of Science ®Google Scholar
• Marzo I, Brenner C, Zamzami N et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J. Exp. Med. 187(8), 1261–1271 (1998).
   PubMedGoogle Scholar
• Kim KH, Seong BL. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J. 22(9), 2104–2116 (2003).
   PubMedGoogle Scholar
• Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272(28), 17255–17257 (1997).
   PubMedGoogle Scholar
• Melegari M, Scaglioni PP, Wands JR. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J. Virol. 72(3), 1737–1743 (1998).
   PubMed Web of Science ®Google Scholar
• Fujii R, Zhu C, Wen Y et al. HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res. 66(18), 9099–9107 (2006).
   PubMedGoogle Scholar
• Wen Y, Golubkov VS, Strongin AY, Jiang W, Reed JC. Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J. Biol. Chem. 283(5), 2793–2803 (2008).
   PubMedGoogle Scholar
• Kim S, Park SY, Yong H et al. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 27(24), 3457–3464 (2008).
   PubMedGoogle Scholar
• Mukherji A, Janbandhu VC, Kumar V. HBx-dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem. J. 401(1), 247–256 (2007).
   PubMedGoogle Scholar
• Chu G, Chang E. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242(4878), 564–567 (1988).
   PubMedGoogle Scholar
• Nichols AF, Itoh T, Graham JA, Liu W, Yamaizumi M, Linn S. Human damage-specific DNA-binding protein p48. Characterization of XPE mutations and regulation following UV irradiation. J. Biol. Chem. 275(28), 21422–21428 (2000).
   PubMedGoogle Scholar
• Shiyanov P, Hayes SA, Donepudi M et al. The naturally occurring mutants of DDB are impaired in stimulating nuclear import of the p125 subunit and E2F1-activated transcription. Mol. Cell Biol. 19(7), 4935–4943 (1999).
   PubMedGoogle Scholar
• Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443(7111), 590–593 (2006).
   PubMed Web of Science ®Google Scholar
• He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20(21), 2949–2954 (2006).
   PubMedGoogle Scholar
• Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell Biol. 8(11), 1277–1283 (2006).
   PubMed Web of Science ®Google Scholar
• Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 72(1), 266–272 (1998).
   PubMed Web of Science ®Google Scholar
• Leupin O, Bontron S, Strubin M. Hepatitis B virus X protein and simian virus 5 V protein exhibit similar UV-DDB1 binding properties to mediate distinct activities. J. Virol. 77(11), 6274–6283 (2003).
   PubMedGoogle Scholar
• Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S303–S309 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas HC. Hepatitis B viral infection. Am. J. Med. 85(2A), 135–140 (1988).
   PubMedGoogle Scholar
• Liu B, Wen X, Huang C, Wei Y. Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years. Int. J. Biochem. Cell Biol. 45(9), 1987–1996 (2013).
   PubMedGoogle Scholar
• Hongthanakorn C, Chotiyaputta W, Oberhelman K et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53(6), 1854–1863 (2011).
   PubMedGoogle Scholar
• Lucifora J, Arzberger S, Durantel D et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. 55(5), 996–1003 (2011).
   PubMed Web of Science ®Google Scholar
• Belloni L, Allweiss L, Guerrieri F et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 122(2), 529–537 (2012).
   PubMed Web of Science ®Google Scholar
• Shin D, Kim SI, Kim M, Park M. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res. 119(2), 146–153 (2006).
   PubMedGoogle Scholar
• Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21(3), 760–766 (1995).
   PubMedGoogle Scholar
• Martin-Vilchez S, Sanz-Cameno P, Rodriguez-Munoz Y et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 47(6), 1872–1883 (2008).
   PubMed Web of Science ®Google Scholar
• Yue X, Yang F, Yang Y et al. Induction of cyclooxygenase-2 expression by hepatitis B virus depends on demethylation-associated recruitment of transcription factors to the promoter. Virol. J. 8, 118 (2011).
   PubMedGoogle Scholar
• Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145–182 (2000).
   PubMed Web of Science ®Google Scholar
• Levrero M, Jean-Jean O, Balsano C, Will H, Perricaudet M. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. Virology 174(1), 299–304 (1990).
   PubMedGoogle Scholar
• Levrero M, Stemler M, Pasquinelli C et al. Significance of anti-HBx antibodies in hepatitis B virus infection. Hepatology 13(1), 143–149 (1991).
   PubMedGoogle Scholar
• Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 25(2), 212–225 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J. Viral Hepat. 16(7), 453–463 (2009).
   PubMed Web of Science ®Google Scholar
• Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin. J. Med. 76(Suppl. 3), S6–S9 (2009).
   PubMedGoogle Scholar
• Nakakura EK, Choti MA. Management of hepatocellular carcinoma. Oncology (Williston Park) 14(7), 1085–1098, discussion 1098–1102 (2000).
   PubMedGoogle Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6), 1752–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 53(2), 348–356 (2010).
   PubMed Web of Science ®Google Scholar
• Bergametti F, Bianchi J, Transy C. Interaction of hepatitis B virus X protein with damaged DNA-binding protein p127: structural analysis and identification of antagonists. J. Biomed. Sci. 9(6 Pt 2), 706–715 (2002).
   PubMedGoogle Scholar
• Urban S, Hildt E, Eckerskorn C, Sirma H, Kekule A, Hofschneider PH. Isolation and molecular characterization of hepatitis B virus X-protein from a baculovirus expression system. Hepatology 26(4), 1045–1053 (1997).
   PubMedGoogle Scholar
• Liu D, Zou L, Li W, Wang L, Wu Y. High-level expression and large-scale preparation of soluble HBx antigen from Escherichia coli. Biotechnol. Appl. Biochem. 54(Pt 3), 141–147 (2009).
   PubMedGoogle Scholar
• Lemmens I, Lievens S, Tavernier J. MAPPIT: a versatile tool to study cytokine receptor signalling. Biochem. Soc. Trans. 36(Pt 6), 1448–1451 (2008).
   PubMedGoogle Scholar
• Yoo YG, Cho S, Park S, Lee MO. The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett. 577(1–2), 121–126 (2004).
   PubMedGoogle Scholar
• Weil R, Sirma H, Giannini C et al. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol. Cell Biol. 19(9), 6345–6354 (1999).
   PubMedGoogle Scholar
• You X, Liu F, Zhang T et al. Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells. Oncogene (2013).
   Google Scholar
• Choi M, Lee H, Rho HM. E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. IUBMB Life 53(6), 309–317 (2002).
   PubMed Web of Science ®Google Scholar
• Wei C, Ni C, Song T et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J. Immunol. 185(2), 1158–1168 (2010).
   PubMed Web of Science ®Google Scholar
• Dorjsuren D, Lin Y, Wei W et al. RMP, a novel RNA polymerase II subunit 5-interacting protein, counteracts transactivation by hepatitis B virus X protein. Mol. Cell Biol. 18(12), 7546–7555 (1998).
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou Y, Sun L et al. Complex formation between heat shock protein 72 and hepatitis B virus X protein in hepatocellular carcinoma tissues. J. Proteome Res. 7(12), 5133–5137 (2008).
   PubMedGoogle Scholar
• Pang R, Lee TK, Poon RT et al. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 132(3), 1088–1103 (2007).
   PubMedGoogle Scholar
• Zhang SM, Sun DC, Lou S et al. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70. Arch. Virol. 150(8), 1579–1590 (2005).
   PubMedGoogle Scholar
• Wei W, Gu JX, Zhu CQ et al. Interaction with general transcription factor IIF (TFIIF) is required for the suppression of activated transcription by RPB5-mediating protein (RMP). Cell Res. 13(2), 111–120 (2003).
   PubMed Web of Science ®Google Scholar
• Lin-Marq N, Bontron S, Leupin O, Strubin M. Hepatitis B virus X protein interferes with cell viability through interaction with the p127-kDa UV-damaged DNA-binding protein. Virology 287(2), 266–274 (2001).
   PubMed Web of Science ®Google Scholar
• Rui E, Moura PR, Goncalves KA, Rooney RJ, Kobarg J. Interaction of the hepatitis B virus protein HBx with the human transcription regulatory protein p120E4F in vitro. Virus Res. 115(1), 31–42 (2006).
   PubMedGoogle Scholar
• Lwa SH, Chen WN. Hepatitis B virus X protein interacts with beta5 subunit of heterotrimeric guanine nucleotide binding protein. Virol. J. 2, 76 (2005).
   PubMedGoogle Scholar
• Shamay M, Barak O, Doitsh G, Ben-Dor I, Shaul Y. Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription. J. Biol. Chem. 277(12), 9982–9988 (2002).
   PubMedGoogle Scholar
• Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 252(5007), 842–844 (1991).
   PubMed Web of Science ®Google Scholar
• Antunovic J, Lemieux N, Cromlish JA. The 17 kDa HBx protein encoded by hepatitis B virus interacts with the activation domains of Oct-1, and functions as a coactivator in the activation and repression of a human U6 promoter. Cell. Mol. Biol. Res. 39(5), 463–482 (1993).
   PubMedGoogle Scholar
• Tan TL, Feng Z, Lu YW, Chan V, Chen WN. Adhesion contact kinetics of HepG2 cells during Hepatitis B virus replication: involvement of SH3-binding motif in HBX. Biochim. Biophys. Acta 1762(8), 755–766 (2006).
   PubMedGoogle Scholar
• Parrish JR, Gulyas KD, Finley RL, Jr. Yeast two-hybrid contributions to interactome mapping. Curr. Opin. Biotechnol. 17(4), 387–393 (2006).
   PubMedGoogle Scholar
• Sambrook J, Russell DW. Detection of protein-protein interactions using the GST fusion protein pulldown technique. CSH Protoc. 2006(1) (2006).
   Google Scholar
• Gregan J, Riedel CG, Petronczki M et al. Tandem affinity purification of functional TAP-tagged proteins from human cells. Nat. Protoc. 2(5), 1145–1151 (2007).
   PubMedGoogle Scholar
• Puig O, Caspary F, Rigaut G et al. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24(3), 218–229 (2001).
   PubMed Web of Science ®Google Scholar
• Bailey D, Urena L, Thorne L, Goodfellow I. Identification of protein interacting partners using tandem affinity purification. J. Vis. Exp. (60) (2012).
   Google Scholar
• Lievens S, Vanderroost N, Van der Heyden J, Gesellchen V, Vidal M, Tavernier J. Array MAPPIT: high-throughput interactome analysis in mammalian cells. J. Proteome Res. 8(2), 877–886 (2009).
   PubMedGoogle Scholar
• Eyckerman S, Verhee A, der Heyden JV et al. Design and application of a cytokine-receptor-based interaction trap. Nat. Cell Biol. 3(12), 1114–1119 (2001).
   PubMedGoogle Scholar
• Uyttendaele I, Lemmens I, Verhee A et al. Mammalian protein-protein interaction trap (MAPPIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor. Mol. Endocrinol. 21(11), 2821–2831 (2007).
   PubMedGoogle Scholar
• Eyckerman S, Lemmens I, Catteeuw D et al. Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat. Methods 2(6), 427–433 (2005).
   PubMedGoogle Scholar
• Barrios-Rodiles M, Brown KR, Ozdamar B et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307(5715), 1621–1625 (2005).
   PubMedGoogle Scholar
• Hashimoto J, Watanabe T, Seki T et al. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format. J. Biomol. Screen. 14(8), 970–979 (2009).
   PubMedGoogle Scholar
• Michnick SW, Ear PH, Landry C, Malleshaiah MK, Messier V. Protein-fragment complementation assays for large-scale analysis, functional dissection and dynamic studies of protein-protein interactions in living cells. Methods Mol. Biol. 756, 395–425 (2011).
   PubMedGoogle Scholar